Document:

Exhibit
10.3

 

VOTING
AGREEMENT

 

THIS
VOTING AGREEMENT (this “Agreement”), is made and entered into as of this 18th day of May, 2020,
by and among ScoutCam Inc., a Nevada corporation (the “Company”), M. Arkin (1999) Ltd. (“Arkin”)
and Medigus Ltd. (“Medigus”) (together with Arkin, the “Stockholders”, and each individually
a “Stockholder”).

 

RECITALS

 

Concurrently
with the execution of this Agreement, the Company and Arkin are entering into a Securities Purchase Agreement providing for the
sale of shares of common stock of the Company, par value $0.001 per share (“Common Stock”), and in connection
with such agreement, the Company agreed to provide Arkin with the right to designate a representative to the board of directors
of the Company (the “Board”).

 

NOW,
THEREFORE, the parties agree as follows:

 

1.
Voting Provisions Regarding Board of Directors.

 

1.1
Designation of Stockholder Board Member. Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such
Stockholder, or over which such Stockholder has voting control, from time to time and at all times, and to take such other actions
required pursuant to the organizational documents of the Company or otherwise, in whatever manner as shall be necessary to ensure
that (A) at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written
consent of the stockholders, (a) one (1) person designated by Arkin shall be elected to the Board, for so long as Arkin, together
with its Affiliates, continues to own beneficially at least eight (8%) of the issued and outstanding capital stock of the Company
(“Arkin Director”), which individual shall initially be Irit Yaniv, unless otherwise provided by Arkin, and
(b) (i) three (3) persons designated by Medigus shall be elected to the Board, for so long as Medigus, together with its Affiliates,
continues to own beneficially at least thirty five (35%) of the issued and outstanding capital stock of the Company, or (ii) two
(2) persons designated by Medigus for so long as Medigus, together with its Affiliates, continues to own beneficially less than
thirty five (35%) and more than twenty (20%) of the issued and outstanding capital stock of the Company, or (iii) one (1) person
designated by Medigus for so long as Medigus, together with its Affiliates, continues to own beneficially less than twenty (20%)
and more than eight (8%) of the issued and outstanding capital stock of the Company (the “Medigus Directors”,
and together with the Arkin Director, the “Stockholders Directors” and each individually a “Stockholder
Director”), which individuals shall initially be Ronen Rosenbloom, Lior Amit and Issac Zilberman, unless otherwise provided
by Medigus; and (B) the size of the Board shall be set and remain at a number that allows for the election of the Stockholders
Directors.

 

For
purposes of this Agreement, the term “Shares” shall mean and include any securities of the Company the holders
of which are entitled to vote for members of the Board, including without limitation, all shares of Common Stock, by whatever
name called, now owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits, stock dividends,
reclassifications, recapitalizations, similar events or otherwise. The term “Affiliate” means, with respect
to any specified Stockholder, any other entity who, directly or indirectly, controls, is controlled by, or is under common control
with such Stockholder, including without limitation any general partner, managing member, officer or director of such Stockholder
or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of,
or shares the same management company with, such Stockholder.

 

    	 

     

    

 

1.2
Failure to Designate a Board Member. In the absence of any designation from Arkin or Medigus, the directors previously
designated by either Arkin or Medigus, as applicable, and then serving shall be reelected if still eligible to serve as provided
herein.

 

1.3
Removal of Board Members. Each Stockholder also agrees to vote, or cause to be voted, all Shares owned by such Stockholder,
or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary
to ensure that: (i) the Stockholders Directors may not be removed from office unless such removal is directed or approved by the
affirmative vote of Arkin in connection with the Arkin Director or Medigus in connection with the Medigus Directors, (ii) any
vacancies created by the resignation, removal or death of a director elected by either Arkin or Medigus shall be filled pursuant
to the provisions of Section ‎1.1, and (iii) upon the written request of Arkin to remove the Arkin Director or Medigus
to remove the Medigus Directors, such director shall be removed.

 

Each
Stockholder agrees to execute any written consents required to perform the obligations of this Agreement, and the Company agrees
at the request of any party entitled to designate directors to call a special meeting of stockholders for the purpose of electing
directors.

 

2.
Covenants of the Company. 

 

The
Company agrees to use its best efforts, within the requirements of applicable law, to ensure that the rights granted under this
Agreement are effective and to cause the nomination and election of the Stockholders Directors as provided in this Agreement.

 

3.
Miscellaneous.

 

3.1
Transfers. The terms of this Agreement shall immediately terminate upon the transfer, sale or disposition of any Shares
subject to this Agreement, with respect to such Shares.

 

3.2
Governing Law. This Agreement shall be governed by and construed in accordance with to the laws of the State of Israel,
disregarding its conflict of laws rules. Any dispute arising under or in relation to this Agreement shall be resolved exclusively
in the competent court located in Tel Aviv-Jaffa, Israel and each of the parties hereby irrevocably submits to the exclusive jurisdiction
of such court.

 

3.3
Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or (a) personal delivery to the party to be notified, (b) when sent,
if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on
the recipient’s next business day (unless sender receives a delivery failure notice, in which case notice shall not be deemed
to be effective), (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) two (2) business days after the deposit with an internationally recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective
parties at their address as set forth below.

 

3.4
Amendment and Waiver; Termination. This Agreement may be amended and the observance of any term hereof may be waived (either
generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (i)
Arkin and (ii) Medigus. This Agreement shall automatically terminate and be of no further force or effect upon the earlier of
(a) the Stockholders mutually agreeing in writing to terminate this Agreement, or (b) such time that each of Medigus and Arkin,
together with such Stockholder’s Affiliates, holds less than eight (8%) of the issued and outstanding capital stock of the
Company, without requiring any further action on the part of the parties.

 

    	 

     

    

 

3.5
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative
and not alternative.

 

3.6
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision.

 

3.7
Entire Agreement. This Agreement and the Company’s charter documents constitute the full and entire understanding
and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating
to the subject matter hereof existing between the parties is expressly canceled.

 

3.8
Further Assurances. At any time or from time to time after the date hereof, the parties agree to cooperate with each other,
and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further
action as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated
hereby and to otherwise carry out the intent of the parties hereunder.

 

3.9
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.

 

[Signature
Page Follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Voting Agreement as of the date first written above.

 

	 	COMPANY
	 	 
	 	SCOUTCAM
    INC.
	 	 
	 	By:
    	/s/
    Yaron Silberman
	 	Name:
    	Yaron Silberman
	 	Title:
    	Chief Executive Officer 
	 	 	 
	 	By:
    	/s/
    Tanya Yosef
	 	Name:
    	Tanya Yosef 
	 	Title:
    	Chief Financial Officer 
	 	 	 
	 	Address:
    Suite 7A, Industrial Park, P.O. Box 3030 Omer, Israel 8496500
	 	 	 
	 	STOCKHOLDERS:
	 	 
	 	M.
    Arkin (1999) Ltd.
	 	 	 
	 	By:
    	/s/
    Mori Arkin
	 	Name:	Mori Arkin 
	 	Title:
    	Director 
	 	 	 
	 	Address:
    Hachoshlim 6, Herzliya, Israel
	 	 	 
	 	Medigus
    Ltd.
	 	 	 
	 	By:
    	/s/
    Liron Carmel
	 	Name:
    	Liron Carmel 
	 	Title:
    	Chief
    Executive Officer
	 	 	 
	 	Address:
    Omer Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, IsraelExhibit
10.4

 

May
18, 2020

 

To:
M. Arkin (1999) Ltd. (“Arkin”)

 

	Re:	Agreements
    as Conditions to Financing

 

Ladies
and Gentlemen:

 

This
letter agreement (this “Letter Agreement”) confirms certain understandings relating to the Spinoff Agreements
(as defined below), which the undersigned, ScoutCam Inc. (the “Company”) and Medigus Ltd. (“Medigus”)
have undertaken to you as condition to your investment in the Company. Reference is made to certain Amended and Restated Asset
Transfer Agreement (the “Asset Agreement”) and that certain Patent License Agreement (the “License
Agreement”, and collectively, the “Spinoff Agreements”), each entered into by and between Medigus
and ScoutCam Ltd., a wholly owned subsidiary of the Company (the “Subsidiary”), dated December 1, 2019. Capitalized
terms not otherwise defined herein shall have the meaning ascribed in the Spinoff Agreements.

 

The
Company and Medigus will take such actions as are reasonably necessary to cause a duly executed amendment of the Spinoff Agreements
to be entered into effect as soon as reasonably practicable and no later than sixty (60) days after the closing of Arkin’s
investment, subject only to obtaining the approval of the Israeli Innovation Authority and Magnet management to the extent legally
necessary with respect to the IIA funded patent assets (and absent any additional contingencies). Such amendment shall have the
effect (without payment of additional consideration) of (i) clarifying and/or supplementing Section 2.1 of the Asset Agreement,
such that the know-how and other intellectual property rights, used or necessary for use in connection with the Transferred Business
shall have been duly transferred to the Subsidiary; and (ii) transferring the patent assets set forth in Appendix A,
and all rights and obligations attached thereto, as Transferred Assets; provided, however, that if the Company decides
to neglect any of the patent assets set forth in Appendix A, the Company shall transfer back ownership of those
patent assets to Medigus, and such transfer shall consist of no additional consideration and absent any additional contingencies.
In the event that the IIA approval and Magnet management cannot be reasonably obtained with respect to the applicable patent,
the amendment shall have the effect of achieving the closest possible result to transfer of exclusive ownership.

 

Each
of the Company and Medigus represents that it has all requisite corporate power and authority to execute and deliver this Letter
Agreement and to carry out and perform its obligations hereunder. This Letter Agreement may not be modified or amended and the
rights of either party hereunder may not be waived unless such modification, amendment, or waiver is effected by a written instrument
signed by the Company, Medigus and Arkin.

 

[Signature
page to follow]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Letter Agreement to be executed as of the date first written above.

 

	 	MEDIGUS:
	 	 	 
	 	 	/s/
    Liron Carmel
	 	 	MEDIGUS
    LTD.
	 	 	 
	 	Name:	Liron
    Carmel
	 	Title:	Chief
    Executive Officer

 

[Medigus
Signature Page to the Letter Agreement]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Letter Agreement to be executed as of the date first written above.

 

	 	THE
                                         COMPANY:

	 	 
	 	SCOUTCAM
    INC. 
	 	 
	 	By:	/s/
    Yaron Silberman           /s/ Tanya Yosef
	 	Name:	Yaron
    Silberman              Tanya Yosef
	 	Title:	Chief
    Executive Officer   Chief Financial Officer
	 	 	 
	 	THE
                                         SUBSIDIARY

	 	 
	 	SCOUTCAM LTD.
	 	 
	 	By:	/s/
    Yaron Silberman          /s/ Tanya Yosef
	 	Name:	Yaron
    Silberman              Tanya Yosef
	 	Title:	Chief
    Executive Officer   Chief Financial Officer

 

[Company
and the Subsidiary Signature Page to the Letter Agreement]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Letter Agreement to be executed as of the date first written above.

 

	 	M.
                                         ARKIN (1999) LTD.

	 	 
	 	By:	/s/
    Mori Arkin
	 	Name:	Mori
    Arkin
	 	Title:	Director

 

[Arkin
Signature Page to the Letter Agreement]

 

    	 

     

    

 

Appendix
A

 

1.
Family 34802

2.
Family 11777

3.
Family 24994

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]